FDA review docs spark Revolution sell-off; Zealand diabetes data underwhelm analysts

T2Covered by 1 source · first reported by BioPharma Dive / Healthcare Dive / MedTech Dive at 09 Oct, 15:18 UTC

The new disclosure suggested Rasonque might not be as broadly effective as previously thought. Elsewhere, Ultragenyx got a much-needed cash infusion and TCGX started a China-focused fund.

science

Sources

• T2FDA review docs spark Revolution sell-off; Zealand diabetes data underwhelm analystsBioPharma Dive / Healthcare Dive / MedTech Dive09 Oct, 15:18